Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The current cornerstone of pain control for rib fractures is oral and intravenous opioids,
especially in the form of patient-controlled analgesia (IV PCA), which are are associated
with multiple adverse effects including sedation, respiratory depression, cough suppression,
and increased risk of delirium.
In the past few decades, intravenous lidocaine infusion (IVL) has emerged as a new tool in
the arsenal of multimodal analgesia. Multiple randomized clinical trials have indicated that
IVL is overall well tolerated and have shown other beneficial effects such as
anti-inflammatory properties. To this date, there have been no published randomized clinical
trials (RCT) evaluating the effectiveness of IVL in management of traumatic rib fracture
pain.
Therefore, the purpose of this study is to evaluate whether IV Lidocaine infusion can provide
improved pain control as demonstrated by decreased OME consumption at 24 and 48 hours
compared to placebo in adult patients with acute traumatic rib fractures.